Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
RXO shares jumped sharply in pre-market trading after the freight brokerage reported second-quarter revenue and earnings that topped analyst forecasts and accompanied those results with an optimistic third-quarter outlook. Volume growth in core brokerage operations and market share gains powered the top-line beat, while elevated analyst expectation…
Dave stock fell sharply in pre-market trading despite beating revenue and adjusted EPS expectations for the second quarter of 2026. While revenue rose 30% year-over-year and management increased full-year guidance, sizable non-cash charges and a large recent run-up in the share price triggered a sell-the-news reaction.
U.S. stock futures were little changed early Thursday as investors monitored reports about a possible agreement to reopen the Strait of Hormuz and wrestled with renewed doubts about the durability of AI-driven spending. Gains in select software and industrial names were offset by weakness in semiconductor and data storage stocks after quarterly res…
Celsius Holdings saw its stock dive in pre-market trade after releasing second-quarter 2026 results that fell short of analyst expectations across profitability and revenue metrics. While companywide revenue rose year-over-year, the core CELSIUS brand posted a double-digit decline, and operating margins narrowed sharply, prompting renewed analyst c…
Alterity Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases, announced that CEO Dr. David Stamler will present at the Canaccord Genuity Growth Conference on August 11, 2026. The company is preparing for a Phase 3 pivotal trial of ATH434 for Multiple System Atrophy (MSA), having shown positive Phase 2 results.…
On Aug. 6, Keurig Dr Pepper reported second-quarter results that exceeded analysts' expectations for both revenue and adjusted earnings per share, driven by strength in its soda and energy beverage portfolios. The company maintained its full-year outlook and reiterated 2026 net sales and adjusted EPS targets as it continues to integrate the JDE Pee…
ConocoPhillips reported second-quarter adjusted earnings that exceeded analyst forecasts, benefiting from stronger crude prices and internal cost reductions even as oil and gas production fell year-over-year. The company cited elevated Brent averages and ongoing regional tensions that have pressured supply chains for some U.S. producers with Middle…
SpaceX reported rapidly improving economics from its AI investments and faster-than-expected revenue growth, but heavy ongoing capital expenditures and investor unease over how long Starlink can underwrite the spending drove the stock sharply lower. Management says new compute deployments are delivering paybacks in under a year and that AI contract…
Warner Bros. Discovery reported second-quarter revenue of $8.72 billion, missing the LSEG estimate of $9.29 billion. The shortfall was driven by a 39% drop in studio revenue and a 22% decline in advertising sales tied to the absence of NBA broadcasts and lower domestic linear TV audiences. Streaming revenue rose 10%, helping deliver a surprise 6-ce…
Appian Corporation announced its financial results for Q2 2026, showing 19% year-over-year total revenue growth to $203.3 million driven by increased cloud subscriptions and professional services. The company improved its GAAP operating loss compared to the prior year and recorded a significant increase in non-GAAP operating income and adjusted EBI…
Lifetime Brands, Inc. announced its financial results for Q2 2026, reporting net sales growth of 7.4% year-over-year and significant earnings improvement driven by a $40.1 million tariff refund. The company repaid $40 million in term debt, showed robust growth in warehouse club and e-commerce channels, and reaffirmed net sales guidance while raisin…
Tarsus Pharmaceuticals announced robust second quarter 2026 financial results driven by 69% year-over-year growth in net product sales of their FDA-approved eye drop XDEMVY for Demodex blepharitis. The company increased its full-year sales guidance and advanced its pipeline with the pending acquisition of Alkeus Pharmaceuticals, adding a Phase 3 cl…
Tarsus Pharmaceuticals announced a $125 million private investment in public equity (PIPE) financing alongside its pending acquisition of Alkeus Pharmaceuticals. The financing garnered participation from existing and new institutional investors, supporting Tarsus' plans to advance clinical development and commercial activities primarily in ophthalm…
Ocugen provided a business update detailing FDA clearance to initiate its Phase 3 trial for OCU410 on geographic atrophy, received RMAT designation, secured a licensing agreement for OCU400 in the Middle East and North Africa, and closed a $130 million convertible senior notes financing. They remain on track for key data readouts in 2027 for their …
Iovance Biotherapeutics reported a record second quarter 2026 revenue of approximately $99 million, a 66% year-over-year increase, driven primarily by strong demand for its commercial product Amtagvi in the U.S. The company improved its gross margin to 56% and is reviewing its full-year 2026 revenue guidance upwards. Clinical progress includes FDA …
Safe Pro Group Inc., a Nasdaq-listed developer of AI-enabled defense and security solutions, announced a $780,000 purchase order from a new Department of War Prime Contractor. The order includes edge AI threat detection technology and Blue UAS drones, with work starting in Q3 2026 and expected completion in Q1 2027. This award marks the fifth recen…
Tarsus Pharmaceuticals announced its definitive agreement to acquire Alkeus Pharmaceuticals, a private biotech focused on retinal diseases, for approximately $450 million upfront plus potential milestones and royalties. The acquisition adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational drug targeting Stargardt disease—a sig…
Gilat Satellite Networks announced a successful demonstration of its breakthrough AI-based interference detection and cancellation technology for satellite links. This patent-pending solution significantly improves interference mitigation by up to 10 times compared to conventional methods, maintaining signal integrity even under challenging interfe…
Aya Gold & Silver Inc. announced the acquisition of a significant exploration portfolio in Morocco, adding 259 km² of land across three projects (Zagora, Agadir-Melloul, and Goulmim). This acquisition increases their total land holdings by 35.4%, strengthens their district-scale exploration strategy, and enhances exposure to precious, base, and cri…
Priovant Therapeutics has commenced patient enrollment in the global Phase 3 BEACON+ trial evaluating brepocitinib for cutaneous sarcoidosis (CS), following positive Phase 2 results and FDA Breakthrough Therapy Designation. The drug is also progressing in multiple orphan disease indications including dermatomyositis, non-infectious uveitis, and lic…
Roivant Sciences reported Q1 FY2027 financial results and provided an update on key pipeline developments. The company is preparing for the commercial launch of brepocitinib for dermatomyositis by September 2026 and expects topline data later this year for several late-stage trials including non-infectious uveitis, cutaneous sarcoidosis, and pulmon…
Immunocore Holdings plc reported robust second quarter 2026 financial results, highlighted by 18% year-over-year growth in net revenues for KIMMTRAK reaching $115.9 million. The company is advancing multiple Phase 3 clinical trials, including the TEBE-AM trial for advanced cutaneous melanoma and the PRISM-MEL-301 trial for first-line melanoma, with…
Korro Bio announced its Q2 2026 financial results, highlighting progress in its OPERA platform technology with the upcoming first-in-human trial for KRRO-121 in hyperammonemia and orphan drug designation from the EMA. The company also nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), demonstrating significant …
Immunovant, a clinical-stage immunology company, announced its financial results for the quarter ended June 30, 2026, highlighting a cash position sufficient to support the potential launch of IMVT-1402 in Graves’ disease. The company reported increased R&D expenses reflecting advancement in clinical trials across six indications including Graves’ …
Cartesian Therapeutics reported Q2 2026 financial results and business updates highlighting progress in its CAR-T cell therapy pipeline targeting autoimmune diseases including myasthenia gravis, myositis, and juvenile dermatomyositis. The company secured a strategic licensing agreement with WestGene to develop an in vivo CAR-T platform, expects mul…
